ERBB2 and breast carcinoma: This is supported by the study that the development of lapatinib resistance of ERBB2-positive breast cancer cells is correlated with upregulation of autophagy where the addition of autophagy inhibitors reversed lapatinib resistance by inhibiting cell proliferation and increasing cell death [51].